José Jiménez-Luna

Dr. José Jiménez-Luna


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 October 2020 in Nature Machine Intelligence
Verified
Journal Article
Open access
PDF file
JJJosé Jiménez-Luna
José Jiménez-Luna
FGFrancesca Grisoni
Francesca Grisoni
GSGisbert Schneider
Gisbert Schneider
Deep learning bears promise for drug discovery, including advanced image analysis, prediction of molecular structure and function, and automated generation of innovative chemical entities with bespoke properties. Despite the growing number of successful prospective applications, the underlying mathematical models often remain elusive to interpretation by the human mind. There is a demand for ‘explainable’ deep learning methods to address the need for a new narrative of the machine language of the molecular sciences. This Review summarizes the most prominent algorithmic concepts of explainable artificial intelligence, and forecasts future opportunities, potential applications as well as several remaining challenges. We also hope it encourages additional efforts towards the development and acceptance of explainable artificial intelligence techniques.

29 January 2018 in Journal of Chemical Information and Modeling
Verified
Journal Article
Closed access
JJJosé Jiménez-Luna
José Jiménez-Luna
MŠMiha Škalič
Miha Škalič
GMGerard Martínez-Rosell
Gerard Martínez-Rosell
GFGianni De Fabritiis
Gianni De Fabritiis

2 April 2021 in Expert Opinion on Drug Discovery
Verified
Journal Article
Open access
JJJosé Jiménez-Luna
José Jiménez-Luna
FGFrancesca Grisoni
Francesca Grisoni
NWNils Weskamp
Nils Weskamp
GSGisbert Schneider
Gisbert Schneider
Introduction: Artificial intelligence (AI) has inspired computer-aided drug discovery. The widespread adoption of machine learning, in particular deep learning, in multiple scientific disciplines, and the advances in computing hardware and software, among other factors, continue to fuel this development. Much of the initial skepticism regarding applications of AI in pharmaceutical discovery has started to vanish, consequently benefitting medicinal chemistry. Areas covered: The current status of AI in chemoinformatics is reviewed. The topics discussed herein include quantitative structure-activity/property relationship and structure-based modeling, de novo molecular design, and chemical synthesis prediction. Advantages and limitations of current deep learning applications are highlighted, together with a perspective on next-generation AI for drug discovery. Expert opinion: Deep learning-based approaches have only begun to address some fundamental problems in drug discovery. Certain methodological advances, such as message-passing models, spatial-symmetry-preserving networks, hybrid de novo design, and other innovative machine learning paradigms, will likely become commonplace and help address some of the most challenging questions. Open data sharing and model development will play a central role in the advancement of drug discovery with AI.

14 August 2025 in Science
Verified
Journal Article
Closed access
SLSarah Lewis
Sarah Lewis
THTim Hempel
Tim Hempel
JJJosé Jiménez-Luna
José Jiménez-Luna
MGMichael Gastegger
Michael Gastegger
YXYu Xie
Yu Xie
FNFrank Noé
Frank Noé
Following the sequence and structure revolutions, predicting functionally relevant protein structure changes at scale remains an outstanding challenge. We introduce BioEmu, a deep learning system that emulates protein equilibrium ensembles by generating thousands of statistically independent structures per hour on a single graphics processing unit (GPU). BioEmu integrates more than 200 milliseconds of molecular dynamics (MD) simulations, static structures, and experimental protein stabilities using new training algorithms. It captures diverse functional motions—including cryptic pocket formation, local unfolding, and domain rearrangements—and predicts relative free energies with 1 kilocalorie per mole accuracy compared with millisecond-scale MD and experimental data. BioEmu provides mechanistic insights by jointly modeling structural ensembles and thermodynamic properties. This approach amortizes the cost of MD and experimental data generation, demonstrating a scalable path toward understanding and designing protein function.

14 February 2019 in Journal of Chemical Information and Modeling
Verified
Journal Article
Closed access
MSMiha Skalic
Miha Skalic
JJJosé Jiménez-Luna
José Jiménez-Luna
DSDavide Sabbadin
Davide Sabbadin
GFGianni De Fabritiis
Gianni De Fabritiis

7 June 2022 in Scientific Data
Verified
Journal Article
Open access
PDF file
CIClemens Isert
Clemens Isert
KAKenneth Atz
Kenneth Atz
JJJosé Jiménez-Luna
José Jiménez-Luna
GSGisbert Schneider
Gisbert Schneider
Machine learning approaches in drug discovery, as well as in other areas of the chemical sciences, benefit from curated datasets of physical molecular properties. However, there currently is a lack of data collections featuring large bioactive molecules alongside first-principle quantum chemical information. The open-access QMugs (Quantum-Mechanical Properties of Drug-like Molecules) dataset fills this void. The QMugs collection comprises quantum mechanical properties of more than 665 k biologically and pharmacologically relevant molecules extracted from the ChEMBL database, totaling ~2 M conformers. QMugs contains optimized molecular geometries and thermodynamic data obtained via the semi-empirical method GFN2-xTB. Atomic and molecular properties are provided on both the GFN2-xTB and on the density-functional levels of theory (DFT, ωB97X-D/def2-SVP). QMugs features molecules of significantly larger size than previously-reported collections and comprises their respective quantum mechanical wave functions, including DFT density and orbital matrices. This dataset is intended to facilitate the development of models that learn from molecular data on different levels of theory while also providing insight into the corresponding relationships between molecular structure and biological activity.